Previous close | 146.81 |
Open | 146.09 |
Bid | 131.30 x 2900 |
Ask | 131.36 x 800 |
Day's range | 131.00 - 147.32 |
52-week range | 19.31 - 189.26 |
Volume | 13,580,787 |
Avg. volume | 19,090,858 |
Market cap | 52.458B |
Beta (5Y monthly) | 1.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.96 |
Earnings date | 05 May 2021 - 10 May 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 168.85 |
Promising clinical trial data bodes well for the biotech's potential entry into the U.S. coronavirus vaccine market.
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
What happened Shares of Moderna (NASDAQ: MRNA) were sinking 7.2% lower as of 12:03 p.m. EST on Wednesday. It marked the second consecutive day of declines for the stock this week. One likely reason behind Moderna's pullback is the entrance of a new rival in the U.